A 24-year-old male is evaluated in the outpatient psychiatry clinic for the management of a recently diagnosed bipolar I disorder. The physician discusses various maintenance medication options, their baseline monitoring requirements, and their characteristic adverse effect profiles. Match each psychotropic medication discussed during the consultation to its correct baseline monitoring requirement and specific adverse effect risk.
- LithiumBaseline thyroid-stimulating hormone and basic metabolic panel; risk of nephrogenic diabetes insipidus
- ValproateBaseline liver function tests and complete blood count; risk of hepatotoxicity and teratogenicity
- LamotrigineNo specific routine baseline laboratory monitoring required; risk of a severe, life-threatening dermatologic reaction
- QuetiapineBaseline fasting lipid panel, hemoglobin A1c, and weight; risk of metabolic syndrome
- SertralineContraindicated as monotherapy in bipolar depression due to the high risk of inducing manic switching
Answer
Lithium matches with baseline TSH/renal function testing. Valproate matches with baseline liver function tests and CBC. Lamotrigine matches with no specific baseline labs. Quetiapine matches with baseline lipid and glucose monitoring. Sertraline matches with being contraindicated as monotherapy.
Each medication correlates with specific clinical monitoring parameters and adverse effects. Lithium uniquely impacts the kidneys and thyroid; valproate impacts the liver and platelets; lamotrigine carries a risk of severe rash without needing baseline labs; quetiapine carries metabolic risks; and sertraline represents the danger of unopposed antidepressant therapy in bipolar disorder.
Step-by-Step Solution
Key Concept
Different mood stabilizers require specific baseline laboratory monitoring based on their unique toxicity profiles. Furthermore, antidepressant monotherapy must be avoided in bipolar disorder due to the risk of manic switching.